3Alonso-Martinez JL, Llorente-Diez B, Echegaray-Agara M, et al. Creactive protein, as a prediction of improvement and read misson inheart failure[J]. Eur J Heart Fail,2002,4(3) :331 -336.
2Colucci WS.Molecular and cellular mechanisms of myocardial failure[J].Am J Cardiol,1997,80:15L-25L.
3Briest W,Holzl A,Rassler B,et al.Cardiac remodeling after long term norepinephrine treatment in rats[J].Cardiovasc Res,2001,52(2):265-273.
4Lijnen PJ,Petrov VV,Fagard RH.Induction of cardiac fibrosis by angiotensin-Ⅱ[J].Methods Find Exp Clin Pharmacol,2000,22(10):709-723.
5Kawano H,Do YS,Kawano Y,et al.Angiotensin Ⅱhas multiple profibrotic effects in human cardiac fibroblasts[J].Circulation,2000,101(10):1130-1137.
6Lijnen P,Petrov V.Induction of cardiac fibrosis by aldosterone[J].Mol Cell Cardiol,2000,32(6):865-879.
7Zannad F,Alla F,Dousset B,et al.Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure:insights from the randomized aldactone evaluation study(RALES).(Rales Investigators)[J].Circulation,2000,102(22):2700-2706.
8Wang D,Liu YH,Yang XP,et al.Role of a selective aldosterone blocker in mice with chronic heart failure [J].Card Fail,2004,10(1):67-73.
9Spninale FG,Coker ML,Heung LJ,et al.A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure[J].Circulation,2000,102:1944-1949.
10Peterson JT.Matrix metalloproteinase inhibitor development and the remodeling of drug discovery[J].Heart Fail Rev,2004,9(1):63-79.
